Keyword: Lexicon Pharmaceuticals
Sanofi doesn't see much of a future for diabetes drug Zynquista, so it's exiting a development partnership with Lexicon.
Increased incidence of diabetic ketoacidosis in Type 1 patients, an issue raised at Zynquista's AdCom meeting, has shown up in other SGLT trials.
The FDA has handed down its decision against Sanofi and Lexicon's Zynquista.
Should the FDA approve Sanofi’s SGLT2 candidate for patients with Type 1 diabetes? Turns out, the experts couldn't agree.